Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Zanidatamab, a HER2-targeted Bispecific Antibody, in Combination With Docetaxel as First-line Therapy for Patients With Advanced HER2-positive Breast Cancer: Updated Results From a Phase 1b/2 Study
Zanidatamab, a HER2-targeted Bispecific Antibody, in Combination With Docetaxel as First-line Therapy for Patients With Advanced HER2-positive Breast Cancer: Updated Results From a Phase 1b/2 Study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study